Reinaldo, Espíndola, Venanzio, Vella, Natividad, Benito, Isabel, Mur, Sara, Tedeschi, Eleonora, Zamparini, Johannes G E, Hendriks, Luisa, Sorlí, Oscar, Murillo, Laura, Soldevila, Mathew, Scarborough, Claire, Scarborough, Jan, Kluytmans, Mateo Carlo, Ferrari, Mathias W, Pletz, Iain, Mcnamara, Rosa, Escudero-Sanchez, Cedric, Arvieux, Cecile, Batailler, Frédéric-Antoine, Dauchy, Wai-Yan, Liu, Jaime, Lora-Tamayo, Julia, Praena, Andrew, Ustianowski, Elisa, Cinconze, Michele, Pellegrini, Fabio, Bagnoli, Jesús, Rodríguez-Baño, Maria Dolores, Del Toro, Gabriella, Lindergard, Hospital Universitario Virgen Macarena [Séville], GlaxoSmithKline [Siena, Italy] (GSK), Hospital de la Santa Creu i Sant Pau, University of Bologna/Università di Bologna, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Department of Orthopaedic Surgery and Trauma, Maxima MC, parent, IMIM-Hospital del Mar, Generalitat de Catalunya, Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), John Radcliffe Hospital [Oxford University Hospital], Amphia Ziekenhuis = Amphia Hospital [Breda, The Netherlands] (AZ=AH), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Jena University Hospital [Jena], Norfolk and Norwich University Hospital, Hospital Universitario Ramón y Cajal [Madrid], Universidad de Alcalá - University of Alcalá (UAH), Hôpital Sud [CHU Rennes], CHU Pontchaillou [Rennes], Laboratoire de Biomécanique et Mécanique des Chocs (LBMC UMR T9406 ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Gustave Eiffel, Centre Hospitalier Universitaire de Bordeaux (CHU de Bordeaux), Catharina Hospital, Hospital Universitario HM Sanchinarro [Madrid, Spain], Hospital Universitario Virgen del Rocío [Sevilla], North Manchester General Hospital, This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement No. 115523), COMBACTE-NET consortium (European Union FP7/2007–2013 and GlaxoSmithKline Biologicals SA, as EFPIA partner). European Development Regional Fund ‘‘A way to achieve Europe’’, Operative Program Intelligence Growth 2014-2020. The study sponsor is also funding the journal’s Rapid Service Fee., European Project: 115523,EC:FP7:SP1-JTI,IMI-JU-06-2012,COMBACTE(2013), European Commission, GlaxoSmithKline, European Federation of Pharmaceutical Industries and Associations, Red Española de Investigación en Patología Infecciosa, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Espíndola, Reinaldo, Vella, Venanzio, Benito, Natividad, Mur, Isabel, Tedeschi, Sara, Zamparini, Eleonora, Hendriks, Johannes G E, Sorlí, Luisa, Murillo, Oscar, Soldevila, Laura, Scarborough, Mathew, Scarborough, Claire, Kluytmans, Jan, Ferrari, Mateo Carlo, Pletz, Mathias W, Mcnamara, Iain, Escudero-Sanchez, Rosa, Arvieux, Cedric, Batailler, Cecile, Dauchy, Frédéric-Antoine, Liu, Wai-Yan, Lora-Tamayo, Jaime, Praena, Julia, Ustianowski, Andrew, Cinconze, Elisa, Pellegrini, Michele, Bagnoli, Fabio, Rodríguez-Baño, Jesú, and Del Toro, Maria Dolores
[Introduction] Guidelines have improved the management of prosthetic joint infections (PJI). However, it is necessary to reassess the incidence and risk factors for treatment failure (TF) of Staphylococcus aureus PJI (SA-PJI) including functional loss, which has so far been neglected as an outcome., [Methods] A retrospective cohort study of SA-PJI was performed in 19 European hospitals between 2014 and 2016. The outcome variable was TF, including related mortality, clinical failure and functional loss both after the initial surgical procedure and after all procedures at 18 months. Predictors of TF were identified by logistic regression. Landmark analysis was used to avoid immortal time bias with rifampicin when debridement, antibiotics and implant retention (DAIR) was performed., [Results] One hundred twenty cases of SA-PJI were included. TF rates after the first and all surgical procedures performed were 32.8% and 24.2%, respectively. After all procedures, functional loss was 6.0% for DAIR and 17.2% for prosthesis removal. Variables independently associated with TF for the first procedure were Charlson ≥ 2, haemoglobin 30 kg/m2 and delay of DAIR, while rifampicin use was protective. For all procedures, the variables associated with TF were haemoglobin, [Conclusions] TF remains common in SA-PJI. Functional loss accounted for a substantial proportion of treatment failures, particularly after prosthesis removal. Use of rifampicin after DAIR was associated with a protective effect. Among the risk factors identified, anaemia and obesity have not frequently been reported in previous studies., [Trial registration] This study is registered at clinicaltrials.gov, registration no. NCT03826108., This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement No. 115523), COMBACTE-NET consortium (European Union FP7/2007–2013 and GlaxoSmithKline Biologicals SA, as EFPIA partner). R.E, L.S, O. M, R. E-S, J. L–T, J. P, J. R-B and MD. del T are members of the Spanish Network for Research in Infectious Diseases (REIPI), supported by Plan Nacional de I + D + i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0005; 0009; 0011; 0015), co‐ financed by European Development Regional Fund “A way to achieve Europe”, Operative Program Intelligence Growth 2014‐2020.